Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001068 | Feeding and Eating Disorders NIH | 0.33 |
| D004194 | Disease NIH | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Most people with an eating disorder (ED) do not receive good treatment. The investigators have developed a new brief group treatment that is supposed to work by reducing how much women with an ED value the impossible thinness standard promoted by the media and how much they value/crave binge foods. The investigators want to test whether the treatment actually changes those two mechanisms using brain scan data, which is more objective than completing questionnaires and even interviews. In the first phase of the study (R61), the investigators will compare women in the treatment versus those on a wait-list. If the investigators can show that the treatment "works" (does what the investigators think it does) compared to no active treatment (women will be allowed to seek and receive outside help but investigators will not provide it until after the wait-list), investigators will conduct the second phase of study (R33),where they will randomly assign women with an ED to either the new treatment or to a group treatment that represents what many college mental health clinics provide to their clients with ED.
Description: Interviewer assesses frequency in binge eating episodes
Measure: Change in occurrences of binge eating episodes using Eating Disorder Diagnostic Interview Time: Week 8; R33 also reviews at 6-month follow-upDescription: Interviewer assesses frequency of compensatory weight control behaviors
Measure: Change in occurrences of compensatory weight control behavior using Eating Disorder Diagnostic Interview Time: Week 8; R33 also reviews at 6-month follow-upDescription: Interviewer assesses change in psychosocial impairment
Measure: Change in psychosocial impairment due to eating disorder symptoms using the Clinical Impairment Assessment Questionnaire Time: Week 8; R33 also reviews at 6-month follow-upDescription: Assess if CAT produces larger pre-post reductions in reward region in response to thin models and binge food (Not collected during COVID-19 shelter-at-home order)
Measure: Change in reward region of the brain using fMRI Time: Week 1 and Week 8Description: Assess if there are any changes in suicide ideation/attempts
Measure: Change in suicidal ideation/attempts using the Patient Health Questionnaire version 9 (PHQ-9) Time: Weeks 2, 4 and 6Description: Assess if there are any changes in negative affect
Measure: Change in negative affect using the Positive Affect and Negative Affect Scale-Revised Time: Weeks 2, 4, and 6Description: Assess if there are any changes in body dissatisfaction
Measure: Change in body dissatisfaction using the Body Dissatisfaction Scale Time: Weeks 2, 4 and 6Description: Assess if there are any changes in food addiction (Only collected during R61 phase)
Measure: Change in food addiction using the Yale Food Addiction Scale version 2.0 Time: Weeks 2, 4, and 6Description: Assess if there are any changes in valuation of the thin beauty ideal
Measure: Change in valuation of thin ideal using the Thin Ideal Valuation Scale Time: Weeks 2, 4, 6, and 8; R33 also reviews at 6-month follow-upDescription: Assess if there are any changes in dietary restraint
Measure: Change in dietary restraint using the 10-item Dutch Restrained Eating Scale Time: Week 8; R33 also reviews at 6-month follow-upDescription: Three implicit association tasks will assess response to binge foods, thin models, and eating disorder behavior words at pre- and post-test (Not collected during COVID-19 shelter-at-home order)
Measure: Change in implicit associations of binge foods, thin models, and eating disorder behavior words Time: Week 8; R33 also reviews at 6-month follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports